OncoCyte Past Earnings Performance
Past criteria checks 0/6
OncoCyte's earnings have been declining at an average annual rate of -3%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 21% per year.
Key information
-3.0%
Earnings growth rate
18.0%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 21.0% |
Return on equity | -97.1% |
Net Margin | -1,716.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How OncoCyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 2 | -26 | 14 | 9 |
30 Sep 23 | 1 | -22 | 16 | 8 |
30 Jun 23 | 1 | -17 | 18 | 7 |
31 Mar 23 | 1 | -11 | 20 | 7 |
31 Dec 22 | 1 | -19 | 22 | 7 |
30 Sep 22 | -1 | -22 | 14 | 2 |
30 Jun 22 | 0 | -34 | 16 | 3 |
31 Mar 22 | 1 | -43 | 19 | 3 |
31 Dec 21 | 2 | -44 | 20 | 5 |
30 Sep 21 | 5 | -35 | 29 | 10 |
30 Jun 21 | 4 | -28 | 26 | 10 |
31 Mar 21 | 2 | -26 | 23 | 11 |
31 Dec 20 | 1 | -30 | 22 | 9 |
30 Sep 20 | 1 | -32 | 22 | 10 |
30 Jun 20 | 0 | -30 | 20 | 9 |
31 Mar 20 | 0 | -26 | 19 | 8 |
31 Dec 19 | 0 | -22 | 15 | 7 |
30 Sep 19 | 0 | -19 | 13 | 5 |
30 Jun 19 | 0 | -17 | 11 | 6 |
31 Mar 19 | 0 | -16 | 9 | 6 |
31 Dec 18 | 0 | -16 | 9 | 6 |
30 Sep 18 | 0 | -15 | 8 | 7 |
30 Jun 18 | 0 | -19 | 12 | 7 |
31 Mar 18 | 0 | -18 | 11 | 7 |
31 Dec 17 | 0 | -19 | 12 | 7 |
30 Sep 17 | 0 | -19 | 11 | 7 |
30 Jun 17 | 0 | -14 | 7 | 7 |
31 Mar 17 | 0 | -13 | 7 | 6 |
31 Dec 16 | 0 | -11 | 5 | 6 |
30 Sep 16 | 0 | -12 | 6 | 6 |
30 Jun 16 | 0 | -11 | 6 | 5 |
31 Mar 16 | 0 | -10 | 5 | 5 |
31 Dec 15 | 0 | -9 | 4 | 5 |
30 Sep 15 | 0 | -7 | 2 | 4 |
30 Jun 15 | 0 | -5 | 1 | 4 |
31 Mar 15 | 0 | -5 | 1 | 4 |
31 Dec 14 | 0 | -5 | 1 | 4 |
Quality Earnings: 0KCC is currently unprofitable.
Growing Profit Margin: 0KCC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0KCC is unprofitable, and losses have increased over the past 5 years at a rate of 3% per year.
Accelerating Growth: Unable to compare 0KCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0KCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: 0KCC has a negative Return on Equity (-97.11%), as it is currently unprofitable.